AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

LISTING OF CLAIMS:

Claims 1 to 48 (Canceled)

49. (Currently amended) A vaccine comprising [an] a recombinant attenuated respiratory syncytial virus, the genome of which contains the reverse complement of an mRNA coding sequence operatively linked to a polymerase binding site of a respiratory syncytial virus, and a pharmaceutically acceptable carrier, wherein the genome comprises a genetic alteration ~~genetic alterations~~.

Claim 50. (Canceled)

51. (Currently amended) The vaccine of claim 49, wherein the genetic alteration is in a [key] regulatory domain.

52. (Currently amended) The vaccine of claim 49, wherein the genetic alteration is in a [key] functional domain.

53. (Previously presented) The vaccine of claim 49, wherein the virus is capable to go through only one round of replication in the host.

54. (new) The vaccine of claim 49, wherein the genetic alteration is a substitution of one or more nucleotides.

55. (new) The vaccine of claim 49, wherein the genetic alteration is an addition of one or more nucleotides.

56. (new) The vaccine of claim 49, wherein the genetic alteration is a deletion of one or more nucleotides.

57. (new) An immunogenic composition comprising a recombinant attenuated respiratory syncytial virus, the genome of which contains the reverse complement of an mRNA coding sequence operatively linked to a polymerase binding site of a respiratory syncytial virus, and a pharmaceutically acceptable carrier, wherein the genome comprises a genetic alteration.

58. (new) An immunogenic composition comprising a recombinant attenuated respiratory syncytial virus, the genome of which contains the reverse complement of an mRNA coding sequence operatively linked to a polymerase binding site of a respiratory syncytial virus, and a pharmaceutically acceptable carrier, wherein the genome comprises a modification not found in the genome of native RSV.

59. (new) The immunogenic composition of claim 57, wherein the genetic alteration is a substitution of one or more nucleotides.

60. (new) The immunogenic composition of claim 57, wherein the genetic alteration is an addition of one or more nucleotides.

61. (new) The immunogenic composition of claim 57, wherein the genetic alteration is a deletion of one or more nucleotides.

62. (new) The immunogenic composition of claim 57, wherein the genetic alteration is in a regulatory domain.

63. (new) The immunogenic composition of claim 57, wherein the genetic alteration is in a functional domain.

64. (new) The immunogenic composition of claim 58, wherein the modification is a substitution of one or more nucleotides.

65. (new) The immunogenic composition of claim 58, wherein the modification is an addition of one or more nucleotides.

66. (new) The immunogenic composition of claim 58, wherein the modification is a deletion of one or more nucleotides.

67. (new) The immunogenic composition of claim 58, wherein the modification is in a regulatory domain.

68. (new) The immunogenic composition of claim 58, wherein the modification is in a functional domain.

69. (new) The immunogenic composition of claim 57 or 58, wherein the virus is capable to go through only one round of replication in the host.

70. (new) A vaccine comprising the immunogenic composition of claim 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, or 69.